687
Iron
- Joined
- Jun 26, 2026
- Posts
- 50
- Reputation
- 25
Ok ok so in this thread/guide I will be teaching you how to grow your clavicles with pharmaceuticals. This is possible at later ages such as early 20s because the clavicles have one of the latest closing growth plates in the human body.
IGF1’s role in clavicle growth and how to maximize it
IGF-1 binds to its receptor, IGFIR, a type of tyrosine kinase receptor that is found on the chondrocyte. This binding causes receptor autophosphorylation and the recruitment of adaptors like IRS and Shc. There are two major signaling pathways, which are PI3K-AKT pathway and the MAPK/ERK pathway.
PIK-AKT pathway: enhances chondrocyte viability, protein synthesis via mTOR, cell proliferation in the proliferative zone and cell hypertrophy. It also aids in the prevention of cell death.
МАРК/ERK pathway: facilitates chondrocyte proliferation and differentiation.
Together, these two pathways drive the elongation of the clavicle bone.
Maxamize IGF1 signaling:
Androgens are largely responsible for the sexual dimorphism observed in clavicles, where males typically develop longer and thicker bones. They do this primarily via 3 ways (indirect and direct).
PTH signaling role in clavicle growth and how to maximize it
Naturally occuring Parathyroid Hormone, or syntheitc agonists like teriparatide/abaloparatide exert strong anabolic effects on bone. These compounds activate the PTH/PTHrP receptor (PTHIR).
The primary signaling route of PTHIR is the Gs protein pathway, which increases intracellular cAMP and activates Protein Kinase A. PKA phosphorylates CREB, driving transcription of key osteogenic factors including Runx2 and Osterix, promoting osteoblast differentiation and bone matrix production. PTHIR also signals through Gq, activating PKC and releasing intracellular calcium, further supporting osteoblast proliferation.
A critical secondary mechanism operates through osteocytes, where PTHIR activation suppresses sclerostin, removing the brake on WNT/b-catenin signaling and amplifying osteoblastogenesis downstream.
At the medial clavicular growth plate (open until early 20s), PTHIR agonism maintains chondrocyte proliferation and delays premature hypertrophy. This is regulated by the PTHrP/Ihh feedback loop, where Indian Hedgehog from prehypertrophic chondrocytes stimulates PTHrP production, slowing chondrocyte progression through the hypertrophic zone and sustaining longitudinal elongation.
Maxamize PTH signaling:
WNT/B-catenin role in clavicle growth and how to maximize it
WNT/3-catenin signaling is critical for osteoblast differentiation, proper chondrocyte maturation, and overall skeletal elongation. It helps direct mesenchymal progenitors toward bone formation rather than cartilage.
WNT ligands bind to Frizzled receptors along with LRP5 or
LRP6 co-receptors. This activates Dishevelled, which inhibits the B-catenin destruction complex (consisting of Axin, GSK3, and CK1). As a result, ß-catenin accumulates in the cytoplasm, translocates into the nucleus, and activates TCF/LEF transcription factors to drive target gene expression.
In the growth plate, this pathway supports chondrocyte hypertrophy and the organized columnar arrangement of cells. In osteoblasts and periosteal cells, it strongly promotes differentiation and bone matrix production. In clavicles, WNT signaling supports both the intramembranous portions and the growth plate mediated lengthening.
Maxamize WNT/b signaling:
NOTE #2: PTHIr agonists (what we talked about on the last slide) ALSO indirectly increase wnt/b signaling to a pretty significant extent, therefor combining abaloparatide/teriparatide with the drugs listed on this slide may lead to diminishing returns (theoretically)
FGFR3 role in limiting clavicle growth and how to inhibit it
FGFR3 acts as a powerful NEGATIVE regulator of endochondral bone growth. In conditions causing an over expression of FGFR3, bones become dramatically shorter, including the clavicles. So FGFR3 likely plays a major limiting role in the clavicles.
Mechanistically, FGFR3 triggers several downstream pathways: STAT1 signaling, which suppresses chondrocyte proliferation; MAPK/ERK signaling, which inhibits both proliferation and proper hypertrophic differentiation while reducing matrix synthesis, and modulation of PLCy and PIK-AKT pathways. The net result is shortened proliferative and hypertrophic zones, disorganized chondrocyte columns, and reduced bone elongation.
Therefore, inhibiting FGFR3 reduces MAPK/ERK and STATI mediated suppression of growth plate chondrocytes, increasing proliferation, clonal expansion, and column length.
(It also permits stronger hypertrophic differentiation and improves
IGF-1/PI3K-AKT signaling.)
Together, this increases growth plate output and endochondral ossification, leading to greater longitudinal bone growth, including in the clavicle.
Inhibit FGFR3:
Estradiol aka (E2) is the primary hormone that accelerates growth plate senescence and causes epiphyseal fusion, limiting final bone length including the clavicles. ERa is the main receptor responsible.
Estradiol enters chondrocytes and binds to ERa, causing receptor dimerization and nuclear translocation. The E2-ERa complex binds to estrogen response elements on DNA and regulates gene transcription, resulting in the following:
Inhibit/Reduce Estradiol
IGF1’s role in clavicle growth and how to maximize it
IGF-1 binds to its receptor, IGFIR, a type of tyrosine kinase receptor that is found on the chondrocyte. This binding causes receptor autophosphorylation and the recruitment of adaptors like IRS and Shc. There are two major signaling pathways, which are PI3K-AKT pathway and the MAPK/ERK pathway.
PIK-AKT pathway: enhances chondrocyte viability, protein synthesis via mTOR, cell proliferation in the proliferative zone and cell hypertrophy. It also aids in the prevention of cell death.
МАРК/ERK pathway: facilitates chondrocyte proliferation and differentiation.
Together, these two pathways drive the elongation of the clavicle bone.
Maxamize IGF1 signaling:
- High dose rHGH (12-22iu+) Facilitates IGF1 Production
- Adequate Insulin (increases hepatic GH receptor expression)
- Androgens (increases localized IGF1 production)
- Adequate Protein Intake (target key amino acids like glycine, arginine, and methionine)
Androgens are largely responsible for the sexual dimorphism observed in clavicles, where males typically develop longer and thicker bones. They do this primarily via 3 ways (indirect and direct).
- Direct - Androgens (like testosterone/DHT) can bind directly to the androgen receptors present in growth-plate chondrocytes. Once the AR is activated through these substrates, it can increase chondrocyte proliferation, matrix/proteoglycan synthesis, and progression through hypertrophy, which expands the cartilage template used for longitudinal bone growth. In endochondral regions of the clavicle (mainly the medial epiphysis).
- Indirect #1 - Androgens can also enhance the growth of your clavicles indirectly by increasing localized IGF-1 production, and sometimes IGF-1 receptor expression within the growth plates. This amplifies IGF-1/РІЗК-АКТ signaling, improving chondrocyte proliferation, survival, and hypertrophy:
- Indirect #2 - Although not actually increasing bone length, androgens can still create the apperance of broader shoulders through stimulating anabolism (growth) in the delts and surrounding muscles.
- Use androgens (duh)
- Preferably stronger options such trenbolone, which
MAY have unique properties in terms of upregulating local IGF1 receptor sensitivity
PTH signaling role in clavicle growth and how to maximize it
Naturally occuring Parathyroid Hormone, or syntheitc agonists like teriparatide/abaloparatide exert strong anabolic effects on bone. These compounds activate the PTH/PTHrP receptor (PTHIR).
The primary signaling route of PTHIR is the Gs protein pathway, which increases intracellular cAMP and activates Protein Kinase A. PKA phosphorylates CREB, driving transcription of key osteogenic factors including Runx2 and Osterix, promoting osteoblast differentiation and bone matrix production. PTHIR also signals through Gq, activating PKC and releasing intracellular calcium, further supporting osteoblast proliferation.
A critical secondary mechanism operates through osteocytes, where PTHIR activation suppresses sclerostin, removing the brake on WNT/b-catenin signaling and amplifying osteoblastogenesis downstream.
At the medial clavicular growth plate (open until early 20s), PTHIR agonism maintains chondrocyte proliferation and delays premature hypertrophy. This is regulated by the PTHrP/Ihh feedback loop, where Indian Hedgehog from prehypertrophic chondrocytes stimulates PTHrP production, slowing chondrocyte progression through the hypertrophic zone and sustaining longitudinal elongation.
Maxamize PTH signaling:
- PTHIR Agonists (Either Abaloparatide, Teriparatide, or rPTH)
- Amplify cAMP by using PDE inhibitors (indirect)
- Adaquate nutrient intake (calcium, magnesium, D3, etc)
WNT/B-catenin role in clavicle growth and how to maximize it
WNT/3-catenin signaling is critical for osteoblast differentiation, proper chondrocyte maturation, and overall skeletal elongation. It helps direct mesenchymal progenitors toward bone formation rather than cartilage.
WNT ligands bind to Frizzled receptors along with LRP5 or
LRP6 co-receptors. This activates Dishevelled, which inhibits the B-catenin destruction complex (consisting of Axin, GSK3, and CK1). As a result, ß-catenin accumulates in the cytoplasm, translocates into the nucleus, and activates TCF/LEF transcription factors to drive target gene expression.
In the growth plate, this pathway supports chondrocyte hypertrophy and the organized columnar arrangement of cells. In osteoblasts and periosteal cells, it strongly promotes differentiation and bone matrix production. In clavicles, WNT signaling supports both the intramembranous portions and the growth plate mediated lengthening.
Maxamize WNT/b signaling:
- Sclerostin Inhibitors (Romozosumab)
- DKK1 Inhibitors (WAY-262611)
- GSK-3b Inhibition (Lithium, Tideglusib)
- Hypertrophy Training (Mechanical strain on osteocytes, suppresses sclerostin, increasing WNT/b signaling)
NOTE #2: PTHIr agonists (what we talked about on the last slide) ALSO indirectly increase wnt/b signaling to a pretty significant extent, therefor combining abaloparatide/teriparatide with the drugs listed on this slide may lead to diminishing returns (theoretically)
FGFR3 role in limiting clavicle growth and how to inhibit it
FGFR3 acts as a powerful NEGATIVE regulator of endochondral bone growth. In conditions causing an over expression of FGFR3, bones become dramatically shorter, including the clavicles. So FGFR3 likely plays a major limiting role in the clavicles.
Mechanistically, FGFR3 triggers several downstream pathways: STAT1 signaling, which suppresses chondrocyte proliferation; MAPK/ERK signaling, which inhibits both proliferation and proper hypertrophic differentiation while reducing matrix synthesis, and modulation of PLCy and PIK-AKT pathways. The net result is shortened proliferative and hypertrophic zones, disorganized chondrocyte columns, and reduced bone elongation.
Therefore, inhibiting FGFR3 reduces MAPK/ERK and STATI mediated suppression of growth plate chondrocytes, increasing proliferation, clonal expansion, and column length.
(It also permits stronger hypertrophic differentiation and improves
IGF-1/PI3K-AKT signaling.)
Together, this increases growth plate output and endochondral ossification, leading to greater longitudinal bone growth, including in the clavicle.
Inhibit FGFR3:
- Erdafitinib
- Infigratinib
- TYRA-300
- Vosoritide (doesn't directly inhibit FGFR3, just counteracts the downstream effects)
Estradiol aka (E2) is the primary hormone that accelerates growth plate senescence and causes epiphyseal fusion, limiting final bone length including the clavicles. ERa is the main receptor responsible.
Estradiol enters chondrocytes and binds to ERa, causing receptor dimerization and nuclear translocation. The E2-ERa complex binds to estrogen response elements on DNA and regulates gene transcription, resulting in the following:
- Decreased chondrocyte proliferation
- Increased chondrocyte apoptosis/senescence
- Accelerated maturation and exhaustion of the chondrocyte pool
- Reduced growth plate height + column density.
Inhibit/Reduce Estradiol
- Aromatase Inhibitors (most effective) e.g, anastrozole, letrozole, aromasin
- Staying at a lower BF% (reduces aromatase expression)
- Lowering testosterone dose (reduces substrates for aromatase)
